期刊文献+

卵巢癌免疫逃逸机制的研究进展 被引量:4

Research advances in mechanism of immune escape in ovarian cancer
下载PDF
导出
摘要 卵巢癌在女性生殖系统恶性肿瘤中死亡率居首位,传统的手术和化疗对其生存率提高有限,免疫治疗是目前充满潜力的肿瘤治疗方式,卵巢癌有效免疫治疗的前提是对其免疫逃逸机制全面深刻的理解。卵巢癌的免疫逃逸机制包括卵巢癌相关抗原无法被识别、抗原递呈细胞的抑制、肿瘤杀伤性免疫细胞的抑制、免疫抑制细胞的激活等。 Ovarian cancer has the highest mortality rate among all malignant tumors of the female reproductive system.The traditional surgery and chemotherapy have the limited effect for increasing its survival rate.Immunotherapy is full of potential for tumor treatment at present.The premise of effective immunotherapy for ovarian cancer is a comprehensive and profound understanding of its immune escape mechanism.The mechanisms of immune escape of ovarian cancer include failure to recognize ovarian cancer-associated antigens,suppression of antigen-presenting cells,suppression of tumor killer immune cells,activation of immunosuppressive cells,etc.
作者 陈俊臣 彭燕蓁(综述) 成九梅(审校) CHEN Junchen;PENG Yanchen;CHENG Jiumei(Gynecological Minimally Invasive Center,Affiliated Beijing Obstetrics and Gynecology Hospital,Capital medical University/ Beijing Maternal and Child Health Care Hospital,Beijing 100006,China)
出处 《重庆医学》 CAS 2022年第10期1769-1773,共5页 Chongqing medicine
基金 首都医科大学附属北京妇产医院中青年学科骨干培养专项(FCYY202105)。
关键词 卵巢癌 免疫逃逸 免疫抑制 机制 免疫治疗 ovarian cancer immune escape immunosuppression mechanism immunotherapy
  • 相关文献

参考文献2

二级参考文献41

  • 1Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. TherAdv Med Onco12014; 6: 229-239.
  • 2Zsiros E, Tanyi J, Balint K, Kandalaft LE. Immunotherapy for ovarian cancer: recent advances and perspectives. CurrOpin 0ncol2014; 26: 492-500.
  • 3Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Onco12010; 117: 366-372.
  • 4Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012; 72: 2162-2171.
  • 5Viehl CT, Moore TT, Liyanage UK, Frey DM, Ehlers JP, Eberlein TJ et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor- specific immune response in pancreas cancer-bearing mice. Ann Surg 0ncol2006; 13: 1252-1258.
  • 6Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z et al. Prognostic significance of FOXP3+ tumor infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res 2014; 16: 432..
  • 7Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Onco12009; 27: 186-192.
  • 8Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Research 2007; 13: 6947-6958.
  • 9Li J, Huang ZF, Xiong G, Mo HY, Qiu F, Mai HQ et al. Distribution, characterization, and induction of CD8+ regulatory T cells and I L-17- producing CD8+ T cells in nasopharyngeal carcinoma. J Transl Med 2011..9: 189.
  • 10Alvarez Arias DA, Kim H J, Zhou P, Holderried TA, Wang X, Dranoff G et al. Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity. Cancer Immunol Res 2014; 2: 207-216.

共引文献25

同被引文献56

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部